Singapore markets closed

Galapagos NV (GLPG)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
38.35-1.06 (-2.70%)
As of 10:41AM EST. Market open.

Galapagos NV

Generaal De Wittelaan L11 A3
Mechelen 2800
32 1 534 29 00

Full-time employees1,338

Key executives

NameTitlePayExercisedYear born
Dr. Paulus A. Stoffels M.D., Ph.D.CEO, Chairman, Interim Head of R&D969.71kN/A1962
Mr. Thad HustonCFO & COON/AN/A1970
Ms. Sofie Van GijselHead of Investor RelationsN/AN/AN/A
Ms. Valeria CnossenGeneral CounselN/AN/AN/A
Marieke VermeerschHead of Corporate CommunicationN/AN/AN/A
Ms. Annelies MissottenChief Human Resources OfficerN/AN/AN/A
Ms. Ellen Van Der AarHead of DevelopmentN/AN/AN/A
Mr. Philippe AlenSenior VP & Head of Business DevelopmentN/AN/AN/A
Mr. Dirk De NaeyerHead of Development OperationsN/AN/AN/A
Ms. Alice DietrichHead of Medical AffairsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG3667 that has completed Phase 1b trial; and GLPG5101 and GLPG5201, CD19 CAR-T product candidate manufactures at point-of-care, that is in Phase I/II in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Corporate governance

Galapagos NV’s ISS governance QualityScore as of 1 February 2024 is 7. The pillar scores are Audit: 6; Board: 4; Shareholder rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.